Extracorporeal Blood Purification Treatment Options for COVID-19: The Role of Immunoadsorption
The activation of theinnate and adaptive immune systems by SARS-CoV-2 causes the release of several inflammatory cytokines, including IL-6. The inflammatory hypercytokinemia causes immunopathological changes in the lungs including vascular leakage, and alveolar edema. As a result of these changes in the lungs, hypoxia and acute respiratory distress syndrome occur in patients with COVID-19. Even though there are clinical trials on the development of therapeutics and vaccines, there are currently no licensed vaccines or therapeutics for COVID-19.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Tu ğçe Nur Yiğenoğlu, Turgay Ulas, Mehmet Sinan Dal, Serdal Korkmaz, Mehmet Ali Erkurt, Fevzi Altuntaş Source Type: research
More News: Clinical Trials | COVID-19 | Hematology | Respiratory Medicine | SARS | Science | Vaccines